


27TH INTERNATIONAL WORKSHOP ON CLINICAL PHARMACOLOGY 2026

OF HIV,
HEPATITIS
AND OTHER
ANTIVIRAL
DRUGS

HYBRID WORKSHOP
2 - 3 SEPTEMBER
MONTREAL,
CANADA



Program

Wednesday, 2 September 2026

Eastern Daylight Time (EDT)

Opening of the Workshop		
11:00 AM	Opening Words Kimberly Scarsi, PharmD, MS, FCCP University of Nebraska Medical Center (UNMC), United States Alice Tseng, B.Sc.Pharm., PharmD, FCSHP, AAHIVP Toronto General Hospital, University of Toronto, Canada Nancy Sheehan, PharmD, MSc, FCSHP Université de Montréal / McGill University Health Centre, Canada	
Session 1: Still Here, Eh? — HIV Persistence in Tissue <i>Co-Chairs: Nancy Sheehan and Melanie Nicol</i>		
11:10 AM	HIV Reservoir and the Persistence of HIV in Tissues Nicolas Chomont, PhD Université de Montréal, Canada	
11:30 AM	Drug Transporters at Blood-Tissue Barriers: Implications for HIV Pharmacotherapy at Sanctuary Sites Reina Bendayan, PharmD University of Toronto, Canada	
11:50 AM	Q&A / Discussion	
Session 2: Driving the Last Spike: Implementing Long-Acting HIV Therapy <i>Co-Chairs: Aaron Devanathan and Kristina Brooks</i>		
12:00 PM	Generic Long Acting ARVs - Bioequivalence Charles Flexner, MD Johns Hopkins University School of Medicine, United States	
<i>Oral Abstract Presentations:</i>		
12:20 PM	Pharmacokinetics of Long-Acting Injectable Cabotegravir without Oral Lead-In in Persons with HIV & Adherence Challenges: Results from ACTG A5359/LATITUDE Alexandra Dunbar - United States	#1
12:30 PM	Long-Acting Cabotegravir/Rilpivirine Therapeutic Drug Monitoring in Patients with HIV Viremia: A Retrospective Study Sébastien Landry - Canada	#2
12:40 PM	Q&A / Discussion	
1:00 PM	Lunch Break	
Session 3: From Prevention to Cure: Hitting the Targets <i>Co-Chairs: Peter Anderson and Adeniyi Olagunju</i>		
2:00 PM	Lenacapavir: Treatment vs Prevention Targets / Can We Extrapolate Aaron S. Devanathan, PharmD, PhD University of Pittsburgh School of Pharmacy, United States	
<i>Oral Abstract Presentations:</i>		
2:20 PM	Population PK Modeling of CAB1600 to Support HIV PrEP Dosed 3 Times a Year Jon Collins - United States	#3
2:30 PM	Pharmacokinetic Insights When Switching from Cabotegravir to Lenacapavir for Pre-exposure Prophylaxis Emily Margaret Thompson - United States	#4

2:40 PM	Real-World Adherence-Response for Viral Suppression Among Adults with HIV-1 in the Modern ART Era: The ACT Study Peter L. Anderson - United States	#5
2:50 PM	A Simplified Enzymatic Assay with Lateral Flow Readout for Point-Of-Care Measurement of Tenofovir Diphosphate and Long-Term HIV Medication Adherence Maya Singh - United States	#6
3:00 PM	Q&A / Discussion	
3:15 PM	Coffee Break	
3:45 PM	Poster Viewing - Odd-numbered Posters	
	ViiV Healthcare-supported Symposium: Understanding Mechanisms of Action: Pharmacological Principles and Clinical Relevance Newer Antiretroviral Compounds	
4:15 PM	Introduction Kimberly Scarsi, PharmD, MS, FCCP University of Nebraska Medical Center (UNMC), United States	
4:20 PM	What's Coming Down the ARV Drug Pipeline? Benoît Lemire, B.Pharm, MSc, FOPQ McGill University Health Centre, Canada	
4:35 PM	How does the Delivery System /Modes of Action Differ for These Newer Agents? Andrew Owen, BSS, MSc, PhD, FSB University of Liverpool, United Kingdom	
4:50 PM	What Are the Clinical Pharmacological Implications? Kristina Brooks, PharmD University of Colorado Anschutz Medical Campus, United States	
5:05 PM	Discussion & Closure of the Symposium Kimberly Scarsi, PharmD, MS, FCCP University of Nebraska Medical Center (UNMC), United States	
	Session 4: Poutine the Pieces Together: Challenging Clinical Cases <i>Co-Chairs: Pierre Giguère and Anushka Naidoo</i>	
	<i>Mini-Oral Abstract Presentations:</i>	
5:15 PM	Supratherapeutic Plasma Concentrations Following Suspected Problematic Cabotegravir/ Rilpivirine Long-Acting Injections: A Case Series Benoît Lemire - Canada	#7
5:22 PM	Initiating Lenacapavir With Increased Dosing in a Patient on Rifabutin: Efficacy and TDM Results Mark McIntyre - Canada	#8
5:29 PM	Use of Daily Rifapentine/Isoniazid (1HP) in a Patient on LA-cabotegravir/rilpivirine: TDM Results Jinell White - Canada	#9
5:36 PM	Doravirine Therapeutic Drug Monitoring after Sleeve Gastrectomy for Weight Loss: A Case Report Kelly Amrud - Canada	#10
5:43 PM	Q&A / Discussion	
6:00 PM	End of Day 1	
7:30 PM	Networking Dinner (<i>for pre-registered attendees</i>)	

Thursday, 3 September 2026

Eastern Daylight Time (EDT)

9:00 AM	Day 2 Opening		
	Session 5: Double-Double, Hold the Interactions: Optimizing Therapy in Patients with Co-infections <i>Co-Chairs: Catia Marzolini and Gilles Peytavin</i>		
9:05 AM	Rifampicin DDIs -with Integrase Inhibitors - When to Modify the Dose? Anushka Naidoo, PhD, MMedSc, BPharm Center for the AIDS Programme of Research in South Africa (CAPRISA), South Africa		
	<i>Oral Abstract Presentations:</i>		
9:25 AM	PBPK Modeling to Recommend AINUOvirine Dosing in HIV and HIV-TB Co-infected Patients: Leveraging Enzyme Auto-Induction and Drug Interactions <i>Liqing Sun - China</i>		#11
9:35 AM	An Exploratory Analysis of the Effect of Genetic Variability on Tenofovir Alafenamide Pharmacokinetics in Adults with HIV-associated Tuberculosis <i>Emmanuel Chinonso Osuala - South Africa</i>		#12
9:45 AM	Q&A / Discussion		
9:55 AM	Coffee Break		
10:25 AM	Poster Viewing - Even-numbered Posters		
	Session 6: À la Mode — Modelling Antiretrovirals, the Future of HIV <i>Co-Chairs: Julie Dumond and Mackenzie Cottrell</i>		
	<i>Oral Abstract Presentations:</i>		
10:55 AM	Model-Informed Drug-Drug Interaction Assessment Predicts No Clinically Meaningful Interaction between Bictegravir and Metamizole <i>Priyanka Arora - United States</i>		#13
11:05 AM	ACC085, A Novel HIV-1 Capsid Function Inhibitor, Exhibits Human Pharmacokinetics Predicted from Nonclinical Data Using a PBPK Model, Supporting its Long-Acting Potential in Humans <i>Hong Qin - China</i>		#14
11:15 AM	Teoreler: A Web-Based Platform for PBPK Simulation and Pharmacokinetic Evaluation Using Cabotegravir Im 800 MG <i>Harshal Sharad Hattiyangdi - United Kingdom</i>		#15
11:25 AM	A Model-Informed Approach to Design a Long-Acting Antiretroviral Implant for Pediatric HIV <i>Jaehyeok Roh - United States</i>		#16
11:35 AM	Q&A / Discussion		

11:45 AM

**Gilead Sciences-supported Symposium:
From PK to Clinical Practice: Long-Acting Antiretrovirals in Diverse Populations**

Welcome

When long-acting meets real-world diversity

Catia Marzolini, PharmD, PhD

University Hospital of Basel, University Hospital of Lausanne, Switzerland / University of Liverpool, United Kingdom

Bridging the gap: Can long-acting antiretroviral therapeutic drug monitoring be useful in clinical practice?

Nancy Sheehan, PharmD, MSc, FCSHP

Université de Montréal / McGill University Health Centre, Canada

How can PK save the day? Strategies for using long-acting antiretrovirals in challenging clinical situations

Alice Tseng, B.Sc.Pharm., PharmD, FCSHP, AAHIVP

Toronto General Hospital, University of Toronto, Canada

Q&A and Close

12:45 PM

Lunch Break

Session 7: Power Play — Tackling Pharmacological Challenges in Key Populations

Co-Chairs: Tim Cressey and Caroline Solas

1:45 PM

Perspectives on the Use of bNabs in Pediatric Treatment

Edmund Capparelli, PharmD

University of California San Diego (UCSD), United States

Oral Abstract Presentations:

2:05 PM

Therapeutic Drug Monitoring of Bictegravir in Children and Adolescents: Is It Useful?

Nancy Sheehan - Canada

#17

2:15 PM

Infant Exposure to Antiretroviral Drugs and HIV RNA in Breastmilk of Women Living with HIV

Wendy van der Wekken-Pas - The Netherlands

#18

2:25 PM

Once Daily Nevirapine Prophylaxis During Breastfeeding in Preterm Infants Using Weight Band Dosing

Edmund Capparelli - United States

#19

2:35 PM

External Evaluation of Dolutegravir Population Pharmacokinetic Models in Children and Adolescents Undergoing Therapeutic Drug Monitoring

Émilie Pilote - Canada

#20

2:45 PM

Q&A / Discussion

3:00 PM

Coffee Break

Session 8: Bienvenue: The Algorithm Has Entered the Chat — AI's Promise and Pitfalls

Chair: Andrew Owen

3:30 PM

The Use of AI in Drug Development and Regulation

Qi Liu, PhD, MStat, FCP

Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration, United States

3:50 PM

The Promise and Potential Pitfalls of AI in Making DDI Calls

Saye Khoo, MD, PhD

Royal Liverpool University Hospital; University of Liverpool, United Kingdom

4:10 PM

Q&A / Discussion

Workshop Closing

4:25 PM

Closing Remarks & Abstract Awards

Kimberly Scarsi, PharmD, MS, FCCP

University of Nebraska Medical Center (UNMC), United States

Alice Tseng, B.Sc.Pharm., PharmD, FCSHP, AAHIVP

Toronto General Hospital, University of Toronto, Canada

Nancy Sheehan, PharmD, MSc, FCSHP

Université de Montréal / McGill University Health Centre, Canada

Acknowledgments

PLATINUM LEVEL SUPPORT



GOLD LEVEL SUPPORT




SILVER LEVEL SUPPORT



ENDORSERS





From PK to Clinical Practice

Long-Acting Antiretrovirals
in Diverse Populations

Thursday, 3 September 2026 • 11:00–12:00 EDT

Le Centre Sheraton Montreal Hotel, Salon ABC
Montreal, Canada

Speakers



Dr Alice Tseng

Pharmacotherapy Specialist, Toronto
General Hospital, and Associate
Professor, University of Toronto



Dr Catia Marzolini

Associate Professor, University
Hospital of Lausanne and University
of Lausanne



Dr Nancy Sheehan

Clinical Professor, University of
Montreal and McGill University
Health Centre

Learning Objectives



Describe the **PK/PD**
principles of **long-acting**
antiretrovirals and **factors**
influencing exposure across
diverse populations



Assess the **rationale**,
evidence, and **limitations**
of **therapeutic drug**
monitoring for long-acting
antiretrovirals



Apply **PK and clinical**
evidence to optimize the
use of long-acting
antiretrovirals in HIV care
in interactive case
discussions

This presentation was developed by the faculty speakers and is intended solely for scientific exchange and educational purposes.

It is non-promotional in nature and is not intended to provide recommendations regarding the use of any product.

Information presented may include data on products or indications that have not been approved by Health Canada.

This symposium is sponsored by Gilead Sciences, Inc.



27TH INTERNATIONAL WORKSHOP ON
CLINICAL PHARMACOLOGY 2026
OF HIV, HEPATITIS AND OTHER ANTIVIRAL DRUGS
HYBRID WORKSHOP | 2 - 3 SEPTEMBER | MONTREAL, CANADA



GILEAD

HIV

